2025 Clinical Practice Guidelines for Hematopoietic Cell Transplantation and CAR-T Therapy

The European Society for Blood and Marrow Transplantation (EBMT) has released its ninth comprehensive report outlining updated clinical practice recommendations for hematopoietic cell transplantation (HCT) and chimeric antigen receptor T-cell (CAR-T) therapies. This influential guide aims to assist healthcare professionals in optimizing treatment strategies for hematological disorders, solid tumors, and immune system diseases.

Over the past twenty years, EBMT has continuously refined its guidelines to keep pace with rapid scientific and clinical advances. The 2025 update emphasizes the importance of standardizing practices across transplant centers to enhance patient outcomes, facilitate data collection, and foster collaborative research. It highlights the expanding role of innovative cellular and gene therapies, such as CAR-T cells and advanced therapy medicinal products (ATMPs), which are now integral to many treatment protocols.

The report provides detailed data, general guidance, and disease-specific tables that offer clear recommendations for HCT and CAR-T therapy indications. These are based on factors like disease status, donor availability, and levels of evidence, with considerations tailored for both adult and pediatric patients. Additional sections address recent advances in gene therapy, underscore the importance of quality standards such as JACIE certification, and advocate for detailed reporting to the EBMT Registry to support long-term outcome studies.

A multidisciplinary approach is strongly advised, balancing the risks of disease progression, procedural complications, and alternative treatment options, all with the goal of maximizing survival and quality of life. Experts such as Raffaella Greco and Annalisa Ruggeri emphasize that these updated guidelines are vital for ensuring consistency, quality, and incorporation of the latest therapeutic innovations across EBMT centers.

This initiative underscores the evolving landscape of cellular and gene therapies, encouraging clinicians worldwide to stay informed and apply these evidence-based recommendations to improve patient care.

For more details, see the full publication in one Marrow Transplantation025, DOI: 10.1038/s41409-025-02701-3.

Source: https://medicalxpress.com/news/2025-10-clinical-haematopoietic-cell-transplantation-car.html